For the twelve months ended Jun 30, 2026, Utah Medical Products Inc. reported $36.11M of revenue and $10.49M of net income.
UTMD revenue was $8.53M in fiscal Q2 2026 (ended Jun 30, 2026), down 14.3% from a year earlier and down 2.2% from the prior quarter. For the full fiscal 2025 it was $38.52M, down 5.8% from fiscal 2024. Compound annual growth was -1.8% over 5 years and -0.4% over 10 years. It rose in 5 of the last 10 fiscal years.
UTMD net income was $2.69M in fiscal Q2 2026 (ended Jun 30, 2026), down 11.9% from a year earlier and up 3.1% from the prior quarter. For the full fiscal 2025 it was $11.29M, down 18.7% from fiscal 2024. Compound annual growth was +0.9% over 5 years and -0.5% over 10 years. It rose in 5 of the last 10 fiscal years.
UTMD diluted EPS was $0.84 in fiscal Q2 2026 (ended Jun 30, 2026), down 10.6% from a year earlier and up 2.4% from the prior quarter. For the full fiscal 2025 it was $3.48, down 12.1% from fiscal 2024. Compound annual growth was +3.4% over 5 years and +1.0% over 10 years.
UTMD free cash flow was $1.25M in fiscal Q2 2026 (ended Jun 30, 2026), down 55.7% from a year earlier and down 58.1% from the prior quarter. For the full fiscal 2025 it was $14.32M, down 1.9% from fiscal 2024. Compound annual growth was -5.8% over 5 years and +0.5% over 10 years. It rose in 6 of the last 10 fiscal years.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.52M | $40.90M | $50.22M | $52.28M | $49.05M | $42.18M | $46.90M | $42.00M | $41.41M | $39.30M |
| Cost of revenue | $16.52M | $16.76M | $20.19M | $20.09M | $18.14M | $16.63M | $17.44M | $15.69M | $15.02M | $15.61M |
| Gross profit | $22.00M | $24.14M | $30.04M | $32.20M | $30.92M | $25.55M | $29.47M | $26.31M | $26.39M | $23.69M |
| Research and development | $668.0K | $813.0K | $560.0K | $493.0K | $526.0K | $486.0K | $483.0K | $454.0K | $447.0K | $475.0K |
| Selling, general and admin | $7.88M | $7.83M | $11.02M | $10.41M | $10.10M | $9.80M | $9.61M | $5.45M | $5.39M | $5.36M |
| Operating income | $11.40M | $13.59M | $16.78M | $19.79M | $18.88M | $13.71M | $17.63M | $18.70M | $19.01M | $16.19M |
| Pre-tax income | $14.11M | $16.80M | $20.09M | $20.66M | $19.06M | $13.84M | $17.88M | $19.46M | $19.08M | $16.42M |
| Income tax | $2.82M | $2.93M | $3.45M | $4.19M | $4.27M | $3.04M | $3.16M | $904.0K | $10.58M | $4.29M |
| Net income | $11.29M | $13.87M | $16.64M | $16.47M | $14.79M | $10.80M | $14.73M | $18.55M | $8.51M | $12.13M |
| EPS, basic | $3.48 | $3.96 | $4.58 | $4.53 | $4.05 | $2.95 | $3.96 | $4.97 | $2.29 | $3.23 |
| EPS, diluted | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 | $2.94 | $3.94 | $4.95 | $2.28 | $3.22 |
| Diluted shares | 3.2M | 3.5M | 3.6M | 3.6M | 3.7M | 3.7M | 3.7M | 3.7M | 3.7M | 3.8M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $85.76M | $82.98M | $92.87M | $75.05M | $60.97M | $51.59M | $42.79M | $51.11M | $39.88M | $26.30M |
| Receivables | $3.52M | $4.09M | $3.39M | $5.54M | $5.13M | $4.10M | $4.74M | $3.96M | $3.62M | $3.21M |
| Inventory | $7.93M | $8.81M | $9.58M | $8.81M | $6.60M | $6.22M | $6.91M | $6.91M | $5.24M | $4.54M |
| Current assets | $97.74M | $96.33M | $106.27M | $89.92M | $73.16M | $62.26M | $54.89M | $60.90M | $49.19M | $34.47M |
| Goodwill | $14.05M | $13.58M | $13.69M | $13.35M | $14.10M | $14.16M | $13.96M | $13.70M | $14.09M | $13.49M |
| Total assets | $122.54M | $122.54M | $135.46M | $123.87M | $115.64M | $111.75M | $109.79M | $99.77M | $92.75M | $76.19M |
| Current liabilities | $2.60M | $3.76M | $4.71M | $5.96M | $3.75M | $3.79M | $3.45M | $5.26M | $5.28M | $3.02M |
| Long-term debt | $225.0K | $282.0K | $295.0K | - | - | - | - | - | - | - |
| Total debt | $225.0K | $282.0K | $295.0K | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Total liabilities | $3.27M | $5.11M | $7.14M | $9.62M | $8.50M | $8.92M | $8.69M | $10.78M | $14.62M | $6.95M |
| Shareholders' equity | $119.27M | $117.43M | $128.31M | $114.25M | $107.14M | $102.82M | $101.09M | $88.99M | $78.12M | $69.24M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.69M | $14.83M | $22.28M | $21.15M | $21.20M | $20.14M | $17.06M | $16.83M | $16.91M | $14.53M |
| Capital expenditures | $371.0K | $230.0K | $639.0K | $809.0K | $552.0K | $860.0K | $540.0K | $402.0K | $1.60M | $3.29M |
| Free cash flow | $14.32M | $14.60M | $21.64M | $20.34M | $20.65M | $19.28M | $16.52M | $16.43M | $15.31M | $11.23M |
| Investing cash flow | -$371.0K | -$208.0K | -$639.0K | -$818.0K | -$552.0K | -$860.0K | -$21.54M | $534.0K | -$1.60M | -$3.30M |
| Financing cash flow | -$12.34M | -$23.84M | -$4.17M | -$5.48M | -$10.90M | -$10.73M | -$4.23M | -$4.78M | -$2.65M | -$6.34M |
| Dividends paid | $3.98M | $4.26M | $4.28M | $3.16M | $11.46M | $4.12M | $4.11M | $4.03M | $2.96M | $3.92M |
| Share repurchases | $8.36M | $19.97M | $0 | $2.50M | $0 | $6.98M | $398.0K | $1.21M | $0 | - |
| Stock-based compensation | $373.0K | $256.0K | $225.0K | $183.0K | $166.0K | $160.0K | $113.0K | $64.0K | $129.0K | $92.0K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -5.8% | -18.6% | -3.9% | 6.6% | 16.3% | -10.1% | 11.7% | 1.4% | 5.4% | -2.1% |
| Net income growth, YoY | -18.7% | -16.6% | 1.0% | 11.4% | 37.0% | -26.7% | -20.6% | 118.2% | -29.9% | 2.4% |
| EPS growth, YoY | -12.1% | -13.3% | 1.1% | 11.9% | 37.4% | -25.4% | -20.4% | 117.1% | -29.2% | 2.5% |
| Gross margin | 57.1% | 59.0% | 59.8% | 61.6% | 63.0% | 60.6% | 62.8% | 62.6% | 63.7% | 60.3% |
| Operating margin | 29.6% | 33.2% | 33.4% | 37.9% | 38.5% | 32.5% | 37.6% | 44.5% | 45.9% | 41.2% |
| Net margin | 29.3% | 33.9% | 33.1% | 31.5% | 30.1% | 25.6% | 31.4% | 44.2% | 20.5% | 30.9% |
| Free cash flow margin | 37.2% | 35.7% | 43.1% | 38.9% | 42.1% | 45.7% | 35.2% | 39.1% | 37.0% | 28.6% |
| Return on equity | 9.5% | 11.8% | 13.0% | 14.4% | 13.8% | 10.5% | 14.6% | 20.9% | 10.9% | 17.5% |
| Return on assets | 9.2% | 11.3% | 12.3% | 13.3% | 12.8% | 9.7% | 13.4% | 18.6% | 9.2% | 15.9% |
| Current ratio | 37.62 | 25.64 | 22.56 | 15.09 | 19.53 | 16.42 | 15.92 | 11.58 | 9.32 | 11.41 |
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.53M | $8.72M | $9.04M | $9.81M | $9.95M | $9.71M | $9.16M | $10.01M | $10.40M | $11.34M | $12.33M | $12.51M |
| Cost of revenue | $3.77M | $3.44M | $3.78M | $4.21M | $4.36M | $4.17M | $3.83M | $4.20M | $4.15M | $4.57M | $5.24M | $5.15M |
| Gross profit | $4.76M | $5.28M | $5.26M | $5.60M | $5.59M | $5.54M | $5.32M | $5.80M | $6.25M | $6.77M | $7.10M | $7.36M |
| Research and development | $154.0K | $154.0K | $212.0K | $167.0K | $135.0K | $154.0K | $121.0K | $172.0K | $255.0K | $266.0K | $146.0K | $138.0K |
| Selling, general and admin | $1.96M | $2.56M | $560.0K | $2.83M | $2.26M | $2.23M | $371.0K | $2.29M | $2.56M | $2.62M | $1.32M | $3.25M |
| Operating income | $2.65M | $2.56M | $2.44M | $2.61M | $3.20M | $3.15M | $2.93M | $3.34M | $3.44M | $3.88M | $3.94M | $3.97M |
| Pre-tax income | $3.29M | $3.18M | $3.11M | $3.31M | $3.84M | $3.86M | $3.61M | $4.18M | $4.21M | $4.80M | $5.02M | $4.78M |
| Income tax | $600.0K | $578.0K | $540.0K | $678.0K | $788.0K | $817.0K | $712.0K | $616.0K | $758.0K | $842.0K | $731.0K | $846.0K |
| Net income | $2.69M | $2.60M | $2.56M | $2.63M | $3.05M | $3.04M | $2.90M | $3.56M | $3.45M | $3.96M | $4.29M | $3.94M |
| EPS, basic | $0.84 | $0.82 | $0.80 | $0.82 | $0.94 | $0.92 | $0.87 | $1.02 | $0.98 | $1.09 | $1.18 | $1.08 |
| EPS, diluted | $0.84 | $0.82 | $0.80 | $0.82 | $0.94 | $0.92 | $0.86 | $1.03 | $0.98 | $1.09 | $1.18 | $1.08 |
| Diluted shares | 3.2M | 3.2M | - | 3.2M | 3.2M | 3.3M | - | 3.5M | 3.5M | 3.6M | - | 3.6M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $87.53M | $87.41M | $85.76M | $84.27M | $82.18M | $83.33M | $82.98M | $88.45M | $89.22M | $93.81M | $92.87M | $88.21M |
| Receivables | $3.56M | $3.64M | $3.52M | $3.73M | $3.63M | $3.94M | $4.09M | $3.72M | $3.67M | $3.59M | $3.39M | $3.49M |
| Inventory | $9.00M | $8.72M | $7.93M | $8.12M | $8.23M | $8.65M | $8.81M | $9.11M | $9.06M | $9.24M | $9.58M | $9.71M |
| Current assets | $100.64M | $100.38M | $97.74M | $96.53M | $94.38M | $96.40M | $96.33M | $101.66M | $102.32M | $107.15M | $106.27M | $101.85M |
| Goodwill | $13.96M | $13.92M | $14.05M | $14.05M | $14.19M | $13.77M | $13.58M | $14.03M | $13.64M | $13.64M | $13.69M | $13.42M |
| Total assets | $124.57M | $124.38M | $122.54M | $121.97M | $120.80M | $122.52M | $122.54M | $129.69M | $130.03M | $135.44M | $135.46M | $131.24M |
| Current liabilities | $2.07M | $3.50M | $2.60M | $3.01M | $2.25M | $4.32M | $3.76M | $3.44M | $3.94M | $5.47M | $4.71M | $4.18M |
| Long-term debt | $195.0K | $210.0K | $225.0K | - | - | $269.0K | $282.0K | - | - | - | $295.0K | - |
| Total debt | $195.0K | $210.0K | $225.0K | - | - | $269.0K | $282.0K | - | - | - | $295.0K | - |
| Total liabilities | $2.54M | $4.01M | $3.27M | $3.72M | $3.27M | $5.47M | $5.11M | $5.50M | $5.98M | $7.70M | $7.14M | $7.54M |
| Shareholders' equity | $122.03M | $120.37M | $119.27M | $118.25M | $117.53M | $117.05M | $117.43M | $124.20M | $124.05M | $127.74M | $128.31M | $123.70M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.38M | $3.11M | $3.48M | $3.88M | $2.87M | $4.46M | $2.94M | $3.86M | $2.76M | $5.28M | $5.33M | $5.12M |
| Capital expenditures | $134.0K | $130.0K | $109.0K | $27.0K | $51.0K | $184.0K | $9.0K | $89.0K | $110.0K | $22.0K | $90.0K | $186.0K |
| Free cash flow | $1.25M | $2.98M | $3.37M | $3.85M | $2.82M | $4.28M | $2.93M | $3.77M | $2.65M | $5.25M | $5.24M | $4.93M |
| Investing cash flow | -$134.0K | -$130.0K | -$109.0K | -$27.0K | -$51.0K | -$184.0K | -$9.0K | -$89.0K | -$115.0K | $5.0K | -$90.0K | -$186.0K |
| Financing cash flow | -$1.06M | -$1.12M | -$1.97M | -$1.64M | -$4.49M | -$4.24M | -$7.75M | -$4.92M | -$7.19M | -$3.98M | -$1.07M | -$1.03M |
| Dividends paid | $987.0K | $989.0K | $977.0K | $988.0K | $1.00M | $1.02M | $1.04M | $1.05M | $1.08M | $1.09M | $1.07M | $1.07M |
| Share repurchases | $78.0K | $128.0K | $994.0K | $653.0K | $3.49M | $3.22M | $6.71M | $3.87M | $6.40M | $2.99M | $0 | $0 |
| Stock-based compensation | $72.0K | $120.0K | $111.0K | $94.0K | $86.0K | $82.0K | $72.0K | $53.0K | $52.0K | $79.0K | $72.0K | $53.0K |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -14.3% | -10.2% | -1.2% | -1.9% | -4.3% | -14.4% | -25.8% | -20.0% | -19.2% | -9.4% | -9.1% | -3.5% |
| Net income growth, YoY | -11.9% | -14.4% | -11.6% | -26.2% | -11.7% | -23.1% | -32.3% | -9.5% | -17.8% | -6.1% | -5.9% | -8.1% |
| EPS growth, YoY | -10.6% | -10.9% | -7.0% | -20.4% | -4.1% | -15.6% | -27.1% | -4.6% | -14.8% | -6.0% | -5.6% | -8.5% |
| Gross margin | 55.8% | 60.6% | 58.2% | 57.1% | 56.2% | 57.0% | 58.1% | 58.0% | 60.1% | 59.7% | 57.6% | 58.8% |
| Operating margin | 31.1% | 29.4% | 27.0% | 26.6% | 32.1% | 32.5% | 32.0% | 33.4% | 33.1% | 34.2% | 32.0% | 31.7% |
| Net margin | 31.5% | 29.9% | 28.4% | 26.8% | 30.6% | 31.3% | 31.7% | 35.6% | 33.2% | 34.9% | 34.8% | 31.5% |
| Free cash flow margin | 14.6% | 34.2% | 37.2% | 39.2% | 28.4% | 44.1% | 32.0% | 37.7% | 25.5% | 46.3% | 42.5% | 39.5% |
| Current ratio | 48.62 | 28.64 | 37.62 | 32.06 | 41.87 | 22.29 | 25.64 | 29.59 | 25.98 | 19.57 | 22.56 | 24.38 |
| Debt to equity | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | - | - | - | 0.00 | - |
Source: XBRL data Utah Medical Products Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| UTMD | $36.11M | -7.0% | $10.49M | 29.0% | $232.0M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |